To Emer Cooke, Executive Director, European Medicines Agency, Amsterdam, The Netherlands 28 February 2021

Dear Sirs/Mesdames,

FOR THE URGENT PERSONAL ATTENTION OF: EMER COOKE, EXECUTIVE DIRECTOR OF THE EUROPEAN MEDICINES AGENCY

As physicians and scientists, we are supportive in principle of the use of new medical interventions which are appropriately developed and deployed, having obtained informed consent from the patient. This stance encompasses vaccines in the same way as therapeutics.

We note that a wide range of side effects is being reported following vaccination of previously healthy younger individuals with the gene-based COVID-19 vaccines. Moreover, there have been numerous media reports from around the world of care homes being struck by COVID-19 within days of vaccination of residents. While we recognise that these occurrences might, every one of them, have been unfortunate coincidences, we are concerned that there has been and there continues to be inadequate scrutiny of the possible causes of illness or death under these circumstances, and especially so in the absence of post-mortems examinations.

In particular, we question whether cardinal issues regarding the safety of the vaccines were adequately addressed prior to their approval by the European Medicines Agency (EMA).

As a matter of great urgency, we herewith request that the EMA provide us with responses to the following issues:

1. Following intramuscular injection, it must be expected that the gene-based vaccines will reach the bloodstream and disseminate throughout the body [1]. We request evidence that this possibility was excluded in pre-clinical animal models with all three vaccines prior to their approval for use in humans by the EMA.

2. If such evidence is not available, it must be expected that the vaccines will remain entrapped in the circulation and be taken up by endothelial cells. There is reason to assume that this will happen particularly at sites of slow blood flow, i.e. in small vessels and capillaries [2]. We request evidence that this probability was excluded in pre-clinical animal models with all three vaccines prior to their approval for use in humans by the EMA.

3. If such evidence is not available, it must be expected that during expression of the vaccines’ nucleic acids, peptides derived from the spike protein will be presented via the MHC I — pathway at the luminal surface of the cells. Many healthy individuals have CD8-lymphocytes that recognize such peptides, which may be due to prior COVID infection, but also to cross-reactions with other types of Coronavirus [3; 4] [5]. We must assume that these lymphocytes will mount an attack on the respective cells. We request evidence that this probability was excluded in pre-clinical animal models with all three vaccines prior to their approval for use in humans by the EMA.

4. If such evidence is not available, it must be expected that endothelial damage with subsequent triggering of blood coagulation via platelet activation will ensue at countless sites throughout the body. We request evidence that this probability was excluded in pre-clinical animal models with all three vaccines prior to their approval for use in humans by the EMA.

5. If such evidence is not available, it must be expected that this will lead to a drop in platelet counts, appearance of D-dimers in the blood, and to myriad ischaemic lesions throughout the body including in the brain, spinal cord and heart. Bleeding disorders might occur in the wake of this novel type of DIC-syndrome including, amongst other possibilities, profuse bleedings and haemorrhagic stroke. We request evidence that all these possibilities were excluded in pre-clinical animal models with all three vaccines prior to their approval for use in humans by the EMA.

6. The SARS-CoV-2 spike protein binds to the ACE2 receptor on platelets, which results in their activation [6]. Thrombocytopenia has been reported in severe cases of SARS-CoV-2 infection [7]. Thrombocytopenia has also been reported in vaccinated individuals [8]. We request evidence that the potential danger of platelet activation that would also lead to disseminated intravascular coagulation (DIC) was excluded with all three vaccines prior to their approval for use in humans by the EMA.

7. The sweeping across the globe of SARS-CoV-2 created a pandemic of illness associated with many deaths. However, by the time of consideration for approval of the vaccines, the health systems of most countries were no longer under imminent threat of being overwhelmed because a growing proportion of the world had already been infected and the worst of the pandemic had already abated. Consequently, we demand conclusive evidence that an actual emergency existed at the time of the EMA granting Conditional Marketing Authorisation to the manufacturers of all three vaccines, to justify their approval for use in humans by the EMA, purportedly because of such an emergency.

Should all such evidence not be available, we demand that approval for use of the gene-based vaccines be withdrawn until all the above issues have been properly addressed by the exercise of due diligence by the EMA.

There are serious concerns, including but not confined to those outlined above, that the approval of the COVID-19 vaccines by the EMA was premature and reckless, and that the administration of the vaccines constituted and still does constitute “human experimentation”, which was and still is in violation of the Nuremberg Code.

In view of the urgency of the situation, we request that you reply to this email within seven days and address all our concerns substantively. Should you choose not to comply with this reasonable request, we will make this letter public.

This email is copied to: Charles Michel, President of the Council of Europe

Ursula von der Leyen, President of the European Commission.

Doctors and scientists can sign the open letter by emailing their name, qualifications, areas of expertise, country and any affiliations they would like to cite, to Doctors4CovidEthics@protonmail.com

References:

[1] Hassett, K. J.; Benenato, K. E.; Jacquinet, E.; Lee, A.; Woods, A.; Yuzhakov, O.; Himansu, S.; Deterling, J.; Geilich, B. M.; Ketova, T.; Mihai, C.; Lynn, A.; McFadyen, I.; Moore, M. J.; Senn, J. J.; Stanton, M. G.; Almarsson, Ö.; Ciaramella, G. and Brito, L. A.2019.Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines, Molecular therapy. Nucleic acids 15 : 1–11

[2] Chen, Y. Y.; Syed, A. M.; MacMillan, P.; Rocheleau, J. V. and Chan, W. C. W. 2020. Flow Rate Affects Nanoparticle Uptake into Endothelial Cells, Advanced materials 32 : 1906274.

[3] Grifoni, A.; Weiskopf, D.; Ramirez, S. I.; Mateus, J.; Dan, J. M.; Moderbacher, C. R.; Rawlings, S. A.; Sutherland, A.; Premkumar, L.; Jadi, R. S. and et al. 2020. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals, Cell 181 : 1489–1501.e15.

[4] Nelde, A.; Bilich, T.; Heitmann, J. S.; Maringer, Y.; Salih, H. R.; Roerden, M.; Lübke, M.; Bauer, J.; Rieth, J.; Wacker, M.; Peter, A.; Hörber, S.; Traenkle, B.; Kaiser, P. D.; Rothbauer, U.; Becker, M.; Junker, D.; Krause, G.; Strengert, M.; Schneiderhan-Marra, N.; Templin, M. F.; Joos, T. O.; Kowalewski, D. J.; Stos-Zweifel, V.; Fehr, M.; Rabsteyn, A.; Mirakaj, V.; Karbach, J.; Jäger, E.; Graf, M.; Gruber, L.-C.; Rachfalski, D.; Preuß, B.; Hagelstein, I.; Märklin, M.; Bakchoul, T.; Gouttefangeas, C.; Kohlbacher, O.; Klein, R.; Stevanović, S.; Rammensee, H.-G. and Walz, J. S.(2020). SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition, Nature immunology.

[5] Sekine, T.; Perez-Potti, A.; Rivera-Ballesteros, O.; Strålin, K.; Gorin, J.-B.; Olsson, A.; Llewellyn-Lacey, S.; Kamal, H.; Bogdanovic, G.; Muschiol, S. and et al. (2020). Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19, Cell 183 : 158–168.e14.

[6] Zhang, S.; Liu, Y.; Wang, X.; Yang, L.; Li, H.; Wang, Y.; Liu, M.; Zhao, X.; Xie, Y.; Yang, Y.; Zhang, S.; Fan, Z.; Dong, J.; Yuan, Z.; Ding, Z.; Zhang, Y. and Hu, L. (2020). SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19, Journal of hematology & oncology 13 : 120.

[7] Lippi, G.; Plebani, M. and Henry, B. M. 2020.Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis, Clin. Chim. Acta 506 : 145–148.

[8] Grady, D. (2021). A Few Covid Vaccine Recipients Developed a Rare Blood Disorder, The New York Times, Feb. 8, 2021.

Yours faithfully,

Professsor Sucharit Bhakdi MD, Professor Emeritus of Medical Microbiology and Immunology, Former Chair, Institute of Medical Microbiology and Hygiene, Johannes Gutenberg University of Mainz (Medical Doctor and Scientist) (Germany and Thailand)

Dr Marco Chiesa MD FRCPsych, Consultant Psychiatrist and Visiting Professor, University College London (Medical Doctor) (United Kingdom and Italy)

Dr C Stephen Frost BSc MBChB Specialist in Diagnostic Radiology, Stockholm, Sweden (Medical Doctor) (United Kingdom and Sweden)

Dr Margareta Griesz-Brisson MD PhD, Consultant Neurologist and Neurophysiologist (studied Medicine in Freiburg, Germany, speciality training for Neurology at New York University, Fellowship in Neurophysiology at Mount Sinai Medical Centre, New York City; PhD in Pharmacology with special interest in chronic low level neurotoxicology and effects of environmental factors on brain health), Medical Director, The London Neurology and Pain Clinic (Medical Doctor and Scientist) (Germany and United Kingdom)

Professor Martin Haditsch MD PhD, Specialist (Austria) in Hygiene and Microbiology, Specialist (Germany) in Microbiology, Virology, Epidemiology/Infectious Diseases, Specialist (Austria) in Infectious Diseases and Tropical Medicine, Medical Director, Travel Med Center, Leonding, Austria, Medical Director, Labor Hannover MVZ GmbH (Medical Doctor and Scientist) (Austria and Germany)

Pharmacologym, European registered Toxicologist, Specialist in Immunology and Immunotoxicology, CEO tpi consult GmbH. (Scientist) (Germany)

Dr Lissa Johnson, BSc BA(Media) MPsych(Clin) PhD, Clinical Psychologist and Behavioural Psychologist, Expertise in the social psychology of torture, atrocity, collective violence and fear propaganda, Former member Australian Psychological Society Public Interest Advisory Group (Clinical Psychologist and Behavioural Scientist) (Australia)

Professor Ulrike Kämmerer PhD, Associate Professor of Experimental Reproductive Immunology and Tumor Biology at the Department of Obstetrics and Gynaecology, University Hospital of Würzburg, Germany, Trained molecular virologist (Diploma, PhD-Thesis) and Immunologist (Habilitation), Remains engaged in active laboratory research (Molecular Biology, Cell Biology (Scientist) (Germany)

Associate Professor Michael Palmer MD, Department of Chemistry (studied Medicine and Medical Microbiology in Germany, has taught Biochemistry since 2001 in present university in Canada; focus on Pharmacology, metabolism, biological membranes, computer programming; experimental research focus on bacterial toxins and antibiotics (Daptomycin); has written a textbook on Biochemical Pharmacology, University of Waterloo, Ontario, Canada (Medical Doctor and Scientist) (Canada and Germany)

Professor Karina Reiss PhD, Professor of Biochemistry, Christian Albrecht University of Kiel, Expertise in Cell Biology, Biochemistry (Scientist) (Germany)

Professor Andreas Sönnichsen MD, Professor of General Practice and Family Medicine, Department of General Practice and Family Medicine, Center of Public Health, Medical University of Vienna, Vienna (Medical Doctor) (Austria)

Dr Michael Yeadon BSc (Joint Honours in Biochemistry and Toxicology) PhD (Pharmacology), Formerly Vice President & Chief Scientific Officer Allergy & Respiratory, Pfizer Global R&D; Co-founder & CEO, Ziarco Pharma Ltd.; Independent Consultant (Scientist) (United Kingdom) of Dr. Pierre Kory MD, before the Homeland Security Committee Meeting on Alternative Treatments for COVID-19 12/08/20(1)

Ref: (1) ChildrensHealthdefense.org

---

Keep Hope Alive Journal Vol 18 N4

pdf printable version of this newsletter

Pierre Kory MD, a critical care respiratory therapist reports that Ivermectin - a low cost generic drug cures Covid-19

Editors Note - Senator Ron Johnson is from Wisconsin and Dr. Pierre Kory MD practices in my hometown of West Allis. Wisconsin, at Aurora St Lukes hospital.

Testimony of Dr. Pierre Kory MD, before the Homeland Security Committee Meeting on Alternative Treatments for COVID-19 12/08/20 Editors Note - Senator Ron Johnson is from Wisconsin and Dr. Pierre Kory MD practices in my hometown of West Allis. Wisconsin, at Aurora St Lukes hospital.

"I want to begin by thanking Senator Ron Johnson and the Committee for this critically needed effort to bring attention to the importance and need for effective early treatment approaches to COVID-19.

I am speaking today not only as an individual physician, but also on behalf of my non-profit organization, the Front-Line COVID-19 Critical Care Alliance, made up of some of the most highly published and well-known critical care experts in the world with almost 2,000 peer -reviewed publications in the medical literature as well as over 100 years of bedside clinical experience in ICU’s around the country.

Although we, like many, are extremely encouraged by the apparent successes in developing effective vaccines, we also are dismayed at the near complete absence of guidance and research on effective early, at-home, or preventative treatment options apart from vaccines, a reality we find unconscionable.

Our hospitals are overflowing with over 100,000 COVID-19 patients admitted, and new record deaths are reported each passing day. It will take months for the vaccine to be distributed to the general public and further time to have sufficient impact in this crisis, so we are here to stress the need for effective early treatment.

My organization of critical care specialists have spent the almost nine months tirelessly reviewing the scientific literature to gain insight into this virus and the disease process and to develop effective treatment protocols.

All the while, we were working long hours in Intensive Care Units full of COVID patients. I
 was proud to testify in front of the committee about our MATH+ Hospital Treatment Protocol in May which I would like to mention has had nearly every single component of its combination therapies validated in clinical studies and our paper detailing and reporting on the impacts of the treatment protocol will be published within days in the Journal of Critical Care Medicine.

And so, it is with great pride as well as significant optimism, that I am here to report that our group, led by Professor Paul E. Marik, has developed a highly effective protocol for preventing and early treatment of COVID-19. In the last 3-4 months, emerging publications provide conclusive data on the profound efficacy of the anti-parasite, anti-viral drug, anti- inflammatory agent called ivermectin in all stages of the disease.

Our protocol was created only recently, after we identified these data. Nearly all studies are demonstrating the therapeutic potency and safety of ivermectin in preventing transmission and progression of illness in nearly all who take the drug.
Before proceeding, I want to bring attention to two critical deficits in our national treatment response that has made this hearing necessary in the first place. Besides the early interest and research into hydroxychloroquine, we can find no other significant efforts to research the use of any other already existing, safe, low-cost therapeutic agents.

Seemingly the only research and treatment focus that we have observed on a national scale is with novel or high-cost pharmaceutically engineered products such as remdesivir, monoclonal antibodies, tocilizumab, with all such therapies costing thousands of dollars. This is consistent with conclusions drawn by a physician consulting to Congress about Covid-19 when she concluded,
“There is a pervasive problem on the Hill with how we prove the value of a low cost treatment.”

Another barrier has been the censorship of all of our attempts at disseminating critical scientific information on Facebook and other social media with our pages repeatedly being blocked. Finally, we believe the lack of clinical experts on the existing task forces is further hindering progress on identifying effective therapeutics.

We can identify almost no members with any similarities to the skill set, clinical knowledge base, and patient care experience to our group of expert clinicians. Existing members all seem to be either physician leaders of large health care organizations or have research backgrounds.

Although many must have had some bedside experience in the care of patients in their careers, there seem to be almost none that have been at the bedside of COVID- 19 patients in any appreciable fashion during this pandemic. Expert clinician panels such as ours have large amounts of valuable insights and wisdom and we are extremely pleased to share our recent discovery of the immense potency of ivermectin in COVID-19.

Ivermectin is highly safe, widely available, and low cost. Its discovery was awarded the Nobel Prize in medicine, and is already included on the WHO’s “World’s List of Essential Medicines.” We now have data from over 20 well-designed clinical studies, ten of them randomized, controlled trials, with every study consistently reporting large magnitude and statistically significant benefits in decreasing transmission rates, shortening recovery times, decreasing hospitalizations, or large reductions in deaths.

This clinical data is also supported by multiple basic science, in-vitro and animal studies. Our manuscript, completed one week ago, is already out of date due to the near daily emergence of new, positive ivermectin studies. The manuscript has been posted on the medical pre-print server OSF (Open Science Foundation) and can be downloaded on our organization’s website, www.flccc.net.

A more updated meta-analysis and review authored by a group of Ph.D. researchers and scientists includes all ivermectin studies as of December 4th, 2020 and can be found on the c19study.com website here: https://ivmmeta.com/
These data show that ivermectin is effectively a “miracle drug” against COVID-19.

The magnitude of the effect is similar to its Nobel prize-worthy historical impacts against parasitic disease across many parts of the globe. It should be noted that that Merck, the pharmaceutical company whose scientists helped discover Ivermectin, has from the first availability of the drug, donated hundreds of millions of doses for free to support the WHO parasite eradication programs.

We believe a similar initiative is needed to eradicate the globe from the scourge of COVID-19. Our group held a press conference this past Friday, December 4th at the United Memorial Medical Center in Houston, issuing a “Call to Action.”

We made a formal request to our national and global health care agencies and leaders to rapidly assess the growing scientific evidence on ivermectin and update treatment guidelines accordingly. We noted that the last treatment recommendation on ivermectin is from August 27th where on the NIH website, they recommended that ivermectin only be used in clinical trials and they based that recommendation as “expert opinion” only given the lack of clinical studies at the time.

There is now a wealth of studies reporting efficacy of ivermectin. In that press conference, we called for a rapid and updated review of this evidence in the hopes a treatment recommendation could be made and thus saving many thousands of lives, quickly. The press conference was broadcast via the Associated Press and Univision to nearly every country globally.

The Health Ministry of the Government of Uganda is currently reviewing our manuscript with the intent of incorporating our treatment protocol into a national treatment guideline. It is now 48 hours later and, although it has been shared widely, we have not heard from:
• Any national news radio, newspaper or television station. 

• Any single member of any U.S health care agency. 

• One notable exception is the interest shown by the Health Ministry of the 
Government of Uganda

We know of no similar effort by any US health care agency at this time. (This point can be omitted if necessary) 
This is unacceptable as we have documented evidence that leading members of Operation Warp Speed, including Janet Woodcock had planned to watch our press conference as have multiple members of the CDC and military as well as journalists from major national news outlets who watched.

Again, 48 hours later and no contact from any health official or major news outlet. We are still hopeful to hear soon from the government and media. 
I now will briefly review and summarize the emerging scientific data demonstrating the efficacy of ivermectin in the treatment of COVID-19

Data Supporting Ivermectin as a Potential Global Solution to the COVID-19 Pandemic 


Ivermectin is already eradicating coronavirus infections in multiple regions of the world. Dozens of studies demonstrate its efficacy from studies done from " bench to the bedside” as follows:

1) Since 2012, multiple in-vitro studies have demonstrated that Ivermectin inhibits the replication of many viruses, including influenza, Zika, Dengue and others (19-27). 

2) Ivermectin inhibits SARS-CoV-2 replication, leading to the absence of nearly all viral material by 48h in infected cell cultures (28). 

3) Ivermectin has potent anti-inflammatory properties with in-vitro data demonstrating profound inhibition of both cytokine production and transcription of nuclear factor-kB (NF-kB), the most potent mediator of inflammation (29-31). 

4) Ivermectin significantly diminishes viral load and protects against organ damage in multiple animal models when infected with SARS-CoV-2 or similar coronaviruses (32, 33). 

5) Ivermectin prevents transmission and development of COVID-19 disease in those exposed to infected patients (34-36,54,88). 

6) Ivermectin hastens recovery and prevents deterioration in patients with mild to moderate disease treated early after symptoms (37-42,54). 

7) Ivermectin hastens recovery and avoidance of ICU admission and death in hospitalized patients (40,43,45,54,63,67). 

8) Ivermectin reduces mortality in critically ill patients with COVID-19 (43,45,54). 

9) Ivermectin leads to striking reductions in case-fatality rates in regions with widespread 
use (46-48). 

10) The safety of ivermectin is nearly unparalleled given its near nil drug interactions along 
with only mild and rare side effects observed in almost 40 years of use and billions of 
doses administered (49). 

11) The World Health Organization has long included ivermectin on its “List of Essential 
Medicines” (50).

A more detailed summary of ivermectin’s existing clinical studies in the prevention, early, and late treatment phases of COVID-19 follows below. All studies are positive, with considerable magnitude benefits, with the vast majority reaching strong statistical significance.

Note that in the below summary, RCT’s refers to "prospective randomized controlled trials" where patients were assigned randomly to a planned treatment with ivermectin or placebo and OCT’s refer to “observational controlled trials" where ivermectin treated patients were compared to concurrently or previously treated patients that did not receive ivermectin.

1) Prevention Studies: Six studies, 4 RCTs, 2 OCT’s with total patients included now over 2,400 patients – all showing near-perfect prevention of transmission of this virus in people with unprotected exposure to COVID-19 patients compared to high measured rates of transmission in those that did not receive ivermectin treatment. 


2) Early treatment: Three RCT’s and multiple large case series –patients in these studies total over 3,000. All studies show either a considerable, statistically significant reduction in the number of patients who deteriorated into hospital or ICU or they reported faster recovery from all symptoms when treated with ivermectin. 


3) Hospital Treatment: Four large RCT’s, 4 well designed OCT’s, total amount of patients studied approach 3,000, and almost all show large and statistically significant reductions in mortality when treated with ivermectin. 

Table 1 below summarizes the existing clinical trials data as of November 24, 2020; however, the number of positive studies has since increased.

Numerous studies have consistently positive reported large magnitudes of benefits in all disease's phases but - with the most significant public health impact in the prevention of transmission. On this compelling evidence, we recommend ivermectin's administration for both prophylaxis in all high-risk patients as well as in the early and late phases of the disease.

If this were to occur nationally and globally, we predict that, like in many of the regions shown above, the pandemic will end, the economy can re-open, social interactions and activity can resume, and life can normalize. The expected impact will allow our nation to grow and focus on the multitude of other pressing problems facing our society.

People are dying at unacceptable and untold rates. I am a lung and ICU specialist, and all I do right now is take care of COVID-19 patients dying of breathlessness in ICUs. By the time they get to the ICU, it is nearly impossible to save most patients.

They simply cannot breathe – all are attached to high flow oxygen delivery devices or non-invasive ventilator masks strapped tight to their faces or they are placed in sedative comas and paralyzed so that mechanical ventilators can do the work of breathing for them. They are dying even with our armory of modern medicines and machines. And they are dying slowly.

I have never witnessed a form of respiratory failure where patients can be consistently kept alive for weeks before finally succumbing. Besides the horrific amount of suffering by the patients, their families are also getting traumatized and destroyed. I have seen so many vibrant fathers and mothers of families die in my ICU. And most importantly, the majority are minorities, black and latino’s, many of them poor and often without access to private doctors for early treatment.

I have never seen such a disparity in any other illness I treat. Recognize that the amount of evidence that I have presented far exceed the level required for a compassionate use authorization as defined by the FDA.
In conclusion, the global impact of the COVID-19 pandemic on both lives and economic despair is in front of all. COVID-19, and the inflammatory response to this virus, ravages damage to the body in a way that we, healthcare providers in the front-line, have never seen before.

The heavy burden placed on society, legislators, governmental and medical organizations is unprecedented. We are worried that if our call to action is not followed through, confidence in our health care leaders and agencies will be irreparably tarnished. Inaction in front of mounting evidence of safety and effectiveness during a catastrophic pandemic may also compromise widespread vaccination support.

We will look back to the impact that actions versus inaction had on the US and the globe two months from now. If we do nothing, the present trend will continue. History will judge. The American people will cry for answers or will praise the courage of those elected to represent their interest.

Table 2. I-MASK+ Prophylaxis & Early Outpatient Treatment Protocol for COVID-19

Outpatient Treatment Protocol for COVID-19
MEDICATION RECOMMENDED DOSING
lvermectin 0.2 mg/kg* dose on day 1 and day 3,
Vitamin D3 - 1000 i.u to 3000 i.u daily
Vitamin C 1000 mg twice daily
Quercetin - 250 mg/day
Melatonin 6 mg before bedtime (causes drowsiness)
Zinc 50 mg/day of elemental zinc
For treating advanced cases of Covid-19 that require hospitalization go to www.flccc.net for more information.

References and Notes
1. Front Line COVID-19 Critical Care Working Group. MATH+ hospital treatment protcol for COVID-19. www.flccc.net. (2020). 

2. . E. Marik, P. Kory, J. Varon, J. Iglesias, G. U. Meduri, MATH+ protocol for the treatment of SARS-CoV-2 infection: the scientific rationale. Expert Review of Anti- infective Therapy. 10.1080/14787210.2020.1808462 (2020). 

3. P. Kory, G. U. Meduri, J Iglesias, J. Varon, P. E. Marik. Clinical and scientific rationale for the MATH+ hospital treatment protocol for COVID-19. J Int Care Med. (2020) (in press).

---

6,000 Covid-19 patients in the Dominican Republic treated with ivermectin.

Excerpts from Dr. José Natalio Redondo of Santo Domingo, Dominican Republic-
Doctors in the Dominican Republic, one of poorest nations in Carribean, have found a safe and effective low cost remedy for Covid-19. The details of this treatment were provided by Dr. José Natalio Redondo, when he participated as a guest in “La Cita con el Covid,” which broadcasts every Monday at 9:00 pm at Listindiario.com.
Redondo reports over that 6,000 Covid-19 positive patients have been successfully treated with excellent results using the drug ivermectin, by doctors belonging to the Rescue group, with health facilities located in Puerto Plata, La Romana, and Punta Cana.

Ivermectin is an antiparasitic and antiviral drug, known and used for 45 years for treating parasitic infections and also used as a dewormer in animals. Rescue doctors in the Dominican Republic used ivermectin to treat patients with the SARS-CoV-2 virus that causes the Covid-19 disease since the beginning of the epidemic.
The advantage of ivermectin, Redondo points out, is that it is a well-known and studied drug because it has been used for more than 30 years in humans. He states that around the world a trillion doses are given per year with no side effects.

The Dose

He explained that the current dose is that a person between 80 and 90 kilos should take six or seven tablets in total, administered all together or in daily doses, preferably in the early stage of symptoms. “Our group is giving it all six (tablets) in the emergency room to Covid patients,” he said. Each tablet has 3 mg of ivermectin. Any doctor may prescribe it.

12/15/20 Reuters News Service reports a new variant of Covid-19 is rapidly spreading in Great Britain.

Reuters reports that mutations to the "spike" protein have occurred. This "spike" protein is what the Covid-19 virus uses to infect human cells. As we reported in our last newsletter, Covid-19 latches onto the ACE2 receptor in the blood vessels and can cause vascular inflammation and blood clots.

Excerpts from Reuters: "The mutations include changes to the important “spike” protein that the SARS-CoV-2 coronavirus uses to infect human cells, a group of scientists tracking the genetics of the virus said, but it is not yet clear whether these are making it more infectious.
"Efforts are under way to confirm whether or not any of these mutations are contributing to increased transmission," the scientists, from the COVID-19 Genomics UK (COG-UK) Consortium, said in a statement (bit.ly/3mhpTJX).
"The new variant, which UK scientists have named “VUI – 202012/01” includes a mutation in the viral genome region encoding the spike protein, which - in theory - could result in COVID-19 spreading more easily between people."

Dec 20 update: With over 1000 Britain's already infected with this new strain of coronavirus, several European countries have blocked travel to and from Britain today. The timing of the emergence of this new variant of the coronavirus is one week after Britain began inoculating its citizens with the Pfizer/BionTech vaccine. Whether this vaccine will protect against the new variant of the Covid-19 virus is unknown at this time.

Australia Abandons Coronavirus Vaccine After Study Participants Test HIV Positive - December 11, 2020

Australia has cancelled an agreement to distribute 51 millions doses of a vaccine made by CSL Limited. The vaccine was abandoned after several persons in the trial receiving the vaccine tested positive with an HIV antibody test.
The Australian Prime Minister, Scott Morrison, stated:
“University of Queensland vaccine will not be able to proceed based on the scientific advice, and that will no longer feature as part of Australia’s vaccine plan."
CSL Ltd used the Covid-19 “spike protein” technology for vaccine research using molecular clamp technology to lock the protein into a shape that allows the immune system to be able to recognize and then neutralize the virus.
Mike Ives of the New York TImes reported the following on Dec 11, 2020:
"The trouble that arose with the Australian vaccine, developed by the University of Queensland and the biotech company CSL, was related to its use of two fragments of a protein found in H.I.V.
"The protein formed part of a molecular “clamp” that researchers placed on the spikes that surround the coronavirus and allow it to enter healthy cells. The clamp stabilizes the spikes, allowing the immune system to respond more effectively to the vaccine.
"The use of the H.I.V. protein posed no risk of infecting the volunteers with that virus, the researchers said. But the clamp generated the production of antibodies recognized by H.I.V. tests at higher levels than the scientists had expected."

The NIH funded research on Coronavirus in bats at Wuhan Lab

The following are excerpts from Newsweek - Dec 20, 2020
"just last year, the National Institute for Allergy and Infectious Diseases, the organization led by Dr. Fauci, funded scientists at the Wuhan Institute of Virology and other institutions for work on gain-of-function research on bat coronaviruses.
"In 2019, with the backing of NIAID, the National Institutes of Health committed $3.7 million over six years for research that included some gain-of-function work. The program followed another $3.7 million, 5-year project for collecting and studying bat coronaviruses, which ended in 2019, bringing the total to $7.4 million.
"Many scientists have criticized gain of function research, which involves manipulating viruses in the lab to explore their potential for infecting humans, because it creates a risk of starting a pandemic from accidental release.
"SARS-CoV-2 , the virus now causing a global pandemic, is believed to have originated in bats. U.S. intelligence, after originally asserting that the coronavirus had occurred naturally, conceded last month that the pandemic may have originated in a leak from the Wuhan lab."
End of quote from Newsweek magazine.

---

---

Medjugorje.org - Our Lady's Message to the world

December 25, 2020

"Dear children! I am carrying to you little Jesus who brings you peace, Him who is the past, present and future of your existence. Little children, do not permit for your faith and hope in a better future to be extinguished, because you are chosen to be witnesses of hope in every situation. That is why I am here with Jesus that He may bless you with His peace. Thank you for having responded to my call."

Keep Hope Alive, PO Box 270041, West Allis, WI 53227 Printed copies Vol. 18 N4 are $3 each 414-231-9817

---

Our Mission and Origin

Conrad LeBeau

Keep Hope Alive was founded to provide self-help information for health conditions deemed chronic, debilitating or hopeless. It has been said that necessity is the mother of invention. The writings of any author are, more often than not, a reflection of their life experiences and education and this website is no exception to those observations. Anyone who states the road back to health is fast and easy is either delusional or deceptive. Health is a sum of many parts and a balancing act for the living. Many parts of the health puzzle will be found here and those who seek solutions for their personal health needs will be rewarded for their efforts, but especially if they apply the knowledge they acquire and are guided by the spirit and their intuition.

Notice: All the information provided on this website is provided free to all who visit here but this website is not a substitute for the medical advice of the health care professional of your choice.

We have been an IRS-approved 501 (c) 3 non-profit organization since 1998. On this web site, we offer a comprehensive source of information on integrative therapies (combining the best of conventional medicine with complementary therapies) with special emphasis on immune-based, dietary, nutritional, herbal, bio-oxidative and other natural therapies for persons immune- compromised that may be affected by HIV, Chronic Fatigue Immune Dysfunction Syndrome (CFIDS), candidiasis, hepatitis, cancer. thyroid and adrenal dysfunction and many other conditions.

Our origin began with publications as early in 1989. In 1991, a book on diet and the immune system soon followed and in Feb..,1995, it was replaced with another book on "How To Reverse Immune Dysfunction." Six editions followed along with several publications including "Progressive Health News" , "Positive Health News" and the current "Journal of Immunity." All are part of this legacy. A treasury of various articles and publications can be found here on a wide variety of health topics. Symptoms and Remedies on this page are a good starting point to search for answers as well as using the Search Box. For economic, global, alternative energy, and environmental issues and solutions. see Keep Hope Alive's Forum Articles link in the right column for reader input and comments as well as the link on Testimonials, read, comment or write here.

Your donations help support our mission to expand the base of knowledge and reach more people. This web site has no annoying advertising or graphics. Your generous donations, tax-deductible, help us continue our mission to "keep hope alive" by providing practical self-help information.

To convert files on this website to any one of over 100 languages such as Spanish, French, German, etc, see instructions at google.com or other websites that have conversion links. Immune Restoration Handbook gives you the best of this website in a single easy to read format with an index of topics covered. Your purchase of the book and your donations help us to keep this website that has benefited many thousands of people.

Thank you for your support. I hope you enjoy this website and gain insights on improving your health from it.

The files in this website are copyrighted by Keep Hope Alive, Ltd. Downloading and printing of files is allowed for personal use only. For more information, contact Keep Hope Alive, PO Box 270041, West Allis, WI 53227. Email: keephopealive @mail.org email phone days 414-two-three-one-9817

Above photo is of the sun rising over Lake Monona, in Madison, Wisconsin. It was provided courtesy of Yinan Chen of www.publicdomainpictures.net/ view-image.php?image=54528&picture=sunrise-over-lake-monona&large=1

FAIR USE NOTICE: This site contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available in our efforts to advance understanding of criminal justice, political, human rights, economic, democracy, scientific, and social justice issues, etc. We believe this constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, the material on this site is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes. For more information go to: http://www.law.cornell.edu/uscode/17/107.shtml. If you wish to use copyrighted material from this site for purposes of your own that go beyond 'fair use', you must obtain permission from the copyright owner.

.